Barclays analyst Iain Simpson upgraded Haleon to Overweight from Equal Weight with a price target of 360 GBp, up from 298 GBp, after after a U.S. federal judge rejected the scientific evidence behind more than 5,000 lawsuits claiming heartburn drug Zantac can cause cancer. Haleon is "investable again" now that the Zantac situation is "substantially derisked," Simpson tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HLN:
